CL2019002839A1 - Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3. - Google Patents

Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.

Info

Publication number
CL2019002839A1
CL2019002839A1 CL2019002839A CL2019002839A CL2019002839A1 CL 2019002839 A1 CL2019002839 A1 CL 2019002839A1 CL 2019002839 A CL2019002839 A CL 2019002839A CL 2019002839 A CL2019002839 A CL 2019002839A CL 2019002839 A1 CL2019002839 A1 CL 2019002839A1
Authority
CL
Chile
Prior art keywords
retina
methods
diseases associated
visual
compositions
Prior art date
Application number
CL2019002839A
Other languages
English (en)
Spanish (es)
Inventor
Laura Coradini
Sam Jackson
Karoly Nikolich
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of CL2019002839A1 publication Critical patent/CL2019002839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2019002839A 2017-04-05 2019-10-04 Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3. CL2019002839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762482134P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
CL2019002839A1 true CL2019002839A1 (es) 2020-06-05

Family

ID=62067800

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002839A CL2019002839A1 (es) 2017-04-05 2019-10-04 Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.

Country Status (20)

Country Link
US (2) US11590118B2 (cg-RX-API-DMAC7.html)
EP (2) EP3606521B1 (cg-RX-API-DMAC7.html)
JP (1) JP7179755B2 (cg-RX-API-DMAC7.html)
KR (1) KR102658724B1 (cg-RX-API-DMAC7.html)
CN (1) CN110650740A (cg-RX-API-DMAC7.html)
AU (2) AU2018248425B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019020430A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058654A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002839A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012336A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992356A1 (cg-RX-API-DMAC7.html)
ES (2) ES2950453T3 (cg-RX-API-DMAC7.html)
IL (1) IL269743B (cg-RX-API-DMAC7.html)
MX (1) MX394915B (cg-RX-API-DMAC7.html)
MY (1) MY199462A (cg-RX-API-DMAC7.html)
NZ (1) NZ757769A (cg-RX-API-DMAC7.html)
SG (1) SG11201909207VA (cg-RX-API-DMAC7.html)
TW (1) TW201841636A (cg-RX-API-DMAC7.html)
UA (1) UA125658C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018187473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382907B2 (en) * 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US12692301B2 (en) * 2020-06-11 2026-07-28 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
CN112322719A (zh) * 2020-11-06 2021-02-05 温州医科大学 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002112800A (ru) 2002-05-16 2004-03-10 Евгений Ильич Зарайский (RU) Способ лечения диабетической ретинопатии
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20140335083A1 (en) 2011-12-01 2014-11-13 Glaxo Group Limited Methods of treatment and prevention of eye diseases
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11382907B2 (en) 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors

Also Published As

Publication number Publication date
KR20190131121A (ko) 2019-11-25
UA125658C2 (uk) 2022-05-11
EP4245295B1 (en) 2025-08-06
KR102658724B1 (ko) 2024-04-18
EP3606521A1 (en) 2020-02-12
US20210106577A1 (en) 2021-04-15
EP3606521B1 (en) 2023-04-19
ES3046717T3 (en) 2025-12-02
AU2024204133B2 (en) 2026-03-26
EP4245295A3 (en) 2023-11-01
AU2018248425B2 (en) 2024-03-28
MX2019012012A (es) 2019-12-11
IL269743B (en) 2022-09-01
JP7179755B2 (ja) 2022-11-29
CO2019012336A2 (es) 2020-04-01
AU2024204133A1 (en) 2024-07-04
EP4245295A2 (en) 2023-09-20
WO2018187473A1 (en) 2018-10-11
ES2950453T3 (es) 2023-10-10
US20240024305A1 (en) 2024-01-25
TW201841636A (zh) 2018-12-01
JP2020513004A (ja) 2020-04-30
EA201992356A1 (ru) 2020-03-23
MX394915B (es) 2025-03-24
NZ757769A (en) 2025-10-31
AU2018248425A1 (en) 2019-10-31
US11951102B2 (en) 2024-04-09
US11590118B2 (en) 2023-02-28
SG11201909207VA (en) 2019-11-28
BR112019020430A2 (pt) 2021-03-30
CN110650740A (zh) 2020-01-03
MY199462A (en) 2023-10-30
IL269743A (en) 2019-11-28
CA3058654A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
MX2022000754A (es) Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
AR098693A1 (es) Método para producir células del epitelio pigmentario retiniano (rpe)
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CO2019012336A2 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX385405B (es) Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.
MY186271A (en) Ophthalmic compositions and methods of use therefor
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CL2016002827A1 (es) Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos.
MX385698B (es) Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
MX2016010215A (es) Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2020004730A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
BR112018006474A2 (pt) nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo
MX2019012985A (es) Métodos para tratar trastornos oculares con antagonistas de aplnr e inhibidores de vegf.
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.